Long Acting Beta2-Agonists Drugs Market- Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025
- Transparency Market Research
- September 2032
- 0 pages
Long-acting beta2-agonists are bronchodilators, a class of asthma medication, taken on a daily basis to relax the smooth muscle lining of bronchial tubes, the airways that carry air to the lungs. It allows the tubes to stay open for a longer period of time to help breathe easily. Long acting beta2-agonists are used to open narrow airways and prevent asthma attacks. These are used in dry powder or metered-dose inhalers. According to the FDA guidelines, long acting beta2-agonists should not be used without being combined with inhaled corticosteroid. Examples of inhaled steroids are Qvar, Flovent, Budesonide, Azmacort, Asmanex, and Aerobid. The most commonly prescribed long acting beta2-agonists are Salmeterol (Serevent), Formoterol (Foradil and Perforomist), and Arformoterol (Brovana).
Long acting beta2-agonists are considered primary drugs of choice to control chronic asthma and chronic obstructive pulmonary disease (COPD), as these make breathing easier. The usage of long acting beta2-agonists in adults with persistent asthma results in improved lung function. Increasing the dose of inhaled corticosteroids results in less use of quick-relief medicines and improves lung function and symptoms.
Ability of the drug to control asthma and rise in the population suffering from asthma and chronic diseases such as COPD are expected to drive the global long acting beta2-agonists drugs market. According to the World Health organization (WHO), in 2015, nearly 383,000 people died due to asthma. Many asthma-related deaths occur in low- and lower-middle income countries. It also stated that approximately 235 million people are presently suffering from asthma and it is a common disease among children.
Moreover, in 2015, chronic obstructive pulmonary disease accounted for 3 million deaths across the world, approximately 5% of all the deaths. The primary cause of chronic obstructive pulmonary disease is exposure to tobacco smoke, either passive or active. The market is expected to expand due to popularity of and preference for long acting beta2-agonists drugs. However, patent and exclusivity expiry of top selling drugs such as Serevent is likely to restrain the global market. The global long acting beta2-agonists drugs market can be segmented based on application, distribution channel, and region. In terms of application, the market can be categorized into asthma and chronic obstructive pulmonary disease (COPD). Based on distribution channel, the global long acting beta2-agonists drugs market can be classified into hospital pharmacies, retail pharmacies, and online pharmacies.
Geographically, the global long acting beta2-agonists drugs market can be segmented into Asia Pacific, Latin America, Europe, North America, and Middle East & Africa. North America held the largest market share in 2016 owing to increase in prevalence of asthma and chronic obstructive pulmonary disease. COPD is the third leading cause of death in the U.S. According to the Centers for Disease Control and Prevention (CDC), nearly 6.4% i.e., 15.7 million, people in the U.S. reported that they had been diagnosed with chronic obstructive pulmonary disease. CDC also stated that nearly 18.4 million people, 7.6% of the total population, aged 18 years and above in the U.S. currently suffer from asthma. Europe accounted for the second largest market share in 2016 owing to increase in prevalence of asthma. According to Asthma U.K., nearly 5.4 million people in the U.K., 1.1 million children (1 in 11) and 4.3 million adults (1 in 12), are currently diagnosed with asthma. The market in Asia Pacific, Latin America, and Middle East & Africa is anticipated to expand during the forecast period owing to increasing population and air pollution.
Key players operating in the global long acting beta2-agonists drugs market include AstraZeneca, Teva Pharmaceutical Industries Ltd., Bayer AG, Actelion Pharmaceuticals US, Inc. Boehringer Ingelheim GmbH, F. Hoffmann-La Roche Ltd., and GlaxoSmithKline plc.
The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.
The study is a source of reliable data on:
- Market segments and sub-segments
- Market trends and dynamics
- Supply and demand
- Market size
- Current trends/opportunities/challenges
- Competitive landscape
- Technological breakthroughs
- Value chain and stakeholder analysis
The regional analysis covers:
- North America (U.S. and Canada)
- Latin America (Mexico, Brazil, Peru, Chile, and others)
- Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)
- Eastern Europe (Poland and Russia)
- Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand)
- Middle East and Africa (GCC, Southern Africa, and North Africa)
The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industry’s value chain.
A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.
Highlights of the report:
- A complete backdrop analysis, which includes an assessment of the parent market
- Important changes in market dynamics
- Market segmentation up to the second or third level
- Historical, current, and projected size of the market from the standpoint of both value and volume
- Reporting and evaluation of recent industry developments
- Market shares and strategies of key players
- Emerging niche segments and regional markets
- An objective assessment of the trajectory of the market
- Recommendations to companies for strengthening their foothold in the market
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.
Have query on this report?Make an Enquiry
The team was the biggest help to us. Not only were we provided with customized solutions but also we were guided through the most complicated situations. The information was on-point yet comprehensive. The experience was absolutely satisfying and helped us turn many challenges into opportunities.
Ours is a startup with a unique set of challenges and we were therefore hesitant but the team totally put us at ease with their knowledge and expertise. Our business and its challenges were understood perfectly and help was extended accordingly. The tailor made approach really helped us gain the most informative insights.
The report repository is absolutely impressive –updated and exhaustive in terms of markets covered and information provides. Besides, with the support extended to us by the team, we could reduce costs as well as move to sustainable growth. This really helped us tap into new opportunities. Happy to have gone ahead with ResearchMos.us.
We have had a long term engagement with ResearchMoz.us and never have we felt that the work done and help extended were below flawless. The report repository is one of the best one can hope to tap into. Recently, our partner businesses opted for consultancy services and they are all thrilled with the outcome.
Insights from reports helped us improve our profit margins significantly. Most of the knowledge we needed on the market were provided to us on a granular basis. From trends, and drivers to competitive analysis, the information was not just crisp but also insightful. That helped us chart a robust growth strategy and as of now we are happy to state that we are reaping big benefits.
More from Pharmaceutical
PharmaceuticalChinese Markets for Mental Illness Drugs
PharmaceuticalChinese Markets for Anti-Dermatomycosis Skin Drugs
PharmaceuticalChinese Markets for Incretion Drugs
PharmaceuticalChinese Markets for Hypertension Drugs
Pharmaceuticals and HealthcareGlobal Bionic Ears Market Professional Survey Report 2017
Pharmaceuticals and HealthcareNeuropsychiatric Disorder Cluster Drug Development Pipeline Review, 2017
Pharmaceuticals and HealthcareHepatitis Drug Development Pipeline Review, 2017